Prezados, bom dia.

Peço que as alunas Thalyne, Talissa e Thallyta desconsiderem o artigo:

 Reich, D. S., Arnold, D. L., Vermersch, P., Bar-Or, A., Fox, R. J., Matta, A., Turner, T., Wallström, E., Zhang, X., Mareš, M., Khabirov, F. A., Traboulsee, A., & Tolebrutinib Phase 2b Study Group (2021). Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial. The Lancet. Neurology, 20(9), 729–738.

O artigo correto é o artigo abaixo:

Hu, X., Cui, Y., White, J., Zhu, Y., Deykin, A., Nestorov, I., & Hung, S. (2015). Pharmacokinetics and pharmacodynamics of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis in the randomized ADVANCE study. British journal of clinical pharmacology, 79(3), 514–522. https://doi.org/10.1111/bcp.12521.